These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 25512404

  • 41. Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model.
    So W, Crandon JL, Nicolau DP.
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4956-61. PubMed ID: 26055376
    [Abstract] [Full Text] [Related]

  • 42. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model.
    Banevicius MA, Kaplan N, Hafkin B, Nicolau DP.
    J Chemother; 2013 Feb; 25(1):26-31. PubMed ID: 23433441
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. In vivo pharmacodynamics of new lipopeptide MX-2401.
    Craig WA, Andes DR, Stamstad T.
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5092-8. PubMed ID: 20855736
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in a murine thigh infection model.
    Watanabe E, Matsumoto K, Ikawa K, Yokoyama Y, Shigemi A, Enoki Y, Umezaki Y, Nakamura K, Ueno K, Terazono H, Morikawa N, Takeda Y.
    J Glob Antimicrob Resist; 2021 Mar; 24():83-87. PubMed ID: 33290889
    [Abstract] [Full Text] [Related]

  • 47. Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP, Noel A, Tomaselli S, Elliott H, Bowker K.
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1436-42. PubMed ID: 21263054
    [Abstract] [Full Text] [Related]

  • 48. In Vivo Pharmacokinetics/Pharmacodynamics of Cefquinome in an Experimental Mouse Model of Staphylococcus Aureus Mastitis following Intramammary Infusion.
    Yu Y, Zhou YF, Chen MR, Li X, Qiao GL, Sun J, Liao XP, Liu YH.
    PLoS One; 2016 Apr; 11(5):e0156273. PubMed ID: 27218674
    [Abstract] [Full Text] [Related]

  • 49. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
    MacGowan AP, Bowker KE, Noel AR.
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1401-6. PubMed ID: 18227179
    [Abstract] [Full Text] [Related]

  • 50. In Vivo Bioluminescent Monitoring of Therapeutic Efficacy and Pharmacodynamic Target Assessment of Antofloxacin against Escherichia coli in a Neutropenic Murine Thigh Infection Model.
    Zhou YF, Tao MT, He YZ, Sun J, Liu YH, Liao XP.
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038275
    [Abstract] [Full Text] [Related]

  • 51. Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole.
    Agudelo M, Vesga O.
    Antimicrob Agents Chemother; 2012 May; 56(5):2659-65. PubMed ID: 22330928
    [Abstract] [Full Text] [Related]

  • 52. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model.
    Smirnova MV, Lubenko IY, Portnoy YA, Zinner SH, Firsov AA.
    Int J Antimicrob Agents; 2007 Feb; 29(2):165-9. PubMed ID: 17207607
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function.
    Huang V, Rybak MJ.
    J Antimicrob Chemother; 2006 Jan; 57(1):116-21. PubMed ID: 16311369
    [Abstract] [Full Text] [Related]

  • 55. In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin against Klebsiella pneumoniae in a Neutropenic Murine Lung Infection Model.
    Zhou YF, Tao MT, Huo W, Liao XP, Sun J, Liu YH.
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264844
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure.
    Hamada Y, Kuti JL, Nicolau DP.
    Antimicrob Agents Chemother; 2016 Feb; 60(2):955-61. PubMed ID: 26621619
    [Abstract] [Full Text] [Related]

  • 59. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
    Firsov AA, Vostrov SN, Lubenko IY, Arzamastsev AP, Portnoy YA, Zinner SH.
    J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
    [Abstract] [Full Text] [Related]

  • 60. In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.
    Zhao M, Lepak AJ, VanScoy B, Bader JC, Marchillo K, Vanhecker J, Ambrose PG, Andes DR.
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378706
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.